ArriVent BioPharma
AVBP
16.89
+1.80
+11.93%
ArriVent BioPharma
US · AVBP
#3057 by market cap
Listed 2024
16.89
+1.80
+11.93%
Live - 5344 symbols - heartbeat 353s ago
· 2026-10-08 09:17
Pre-market
16.57
-1.89%
After-hours
17.10
+1.24%
Overnight
16.89
0.00%
- Market cap
- 832.81M
- P/E (TTM)i
- -4.76
- P/Bi
- 2.27
- EPSi
- -4.32
- Div yieldi
- 0.00%
- 52W posi
- 23%
Reader sentiment
Are you bullish or bearish on AVBP?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 2.5 percentage points.
Institutional ownership
- Held by institutions
- 103.13% -2.51pp
- Institutions
- 193 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund37.61%
Hedge Fund31.81%
Mutual Fund29.61%
Public Company2.49%
Individual/Insider1.82%
Private Company1.39%
Government Pension Fund0.18%
Top holders as of 2026-06-30
Montanova Capital, LLC
9.16% · 4.52M sh
Infinitum Asset Management, LLC
9.00% · 4.44M sh
Hillhouse Capital Management, Ltd.
7.97% · 3.93M sh
BlackRock
6.59% · 3.25M sh
OrbiMed Advisors LLC
6.14% · 3.03M sh
FMR
5.64% · 2.78M sh
HBM Healthcare Investments AG
4.45% · 2.20M sh
Eli Lilly Investment Consulting (Shanghai) Co., Ltd.
4.15% · 2.05M sh
Vanguard Capital Management, LLC
4.13% · 2.03M sh
Octagon Capital Advisors LP
4.00% · 1.97M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
47 filings tracked · 29 buys · 1 sells
| Name | Role | Stake |
|---|---|---|
| Robin LaChapelle | Co-Founder & COO | 1.08% |
| Zhengbin Yao | Chairperson & CEO | 0.44% |
| Stuart Lutzker | Co-Founder, President of Research & Development and Director | 0.30% |
| Kristine Peterson | Director | -- |
| Hillhouse Capital Management, Ltd. | -- | -- |
| Merdad Parsey | Independent Director | -- |
| John Hohneker | Director | -- |
| Winston Kung | Chief Financial Officer | -- |
| Christian Nolet | Independent Director | -- |
| James Kastenmayer | General Counsel | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-17 | Kristine Peterson | Director | Other Derivative Acquisition | +13,562 | $31.74 |
| 2026-06-17 | Merdad Parsey | Independent Director | Other Derivative Acquisition | +13,562 | $31.74 |
| 2026-06-17 | John Hohneker | Director | Other Derivative Acquisition | +13,562 | $31.74 |
| 2026-06-17 | Christian Nolet | Independent Director | Other Derivative Acquisition | +13,562 | $31.74 |
| 2026-02-01 | Zhengbin Yao | Chairperson & CEO | Other Derivative Acquisition | +550,000 | $22.67 |
| 2026-02-01 | Robin LaChapelle | Co-Founder & COO | Other Derivative Acquisition | +130,000 | $22.67 |
| 2026-02-01 | Stuart Lutzker | Co-Founder, President of Research & Development and Director | Other Derivative Acquisition | +150,000 | $22.67 |
| 2026-02-01 | Winston Kung | Chief Financial Officer | Other Derivative Acquisition | +140,000 | $22.67 |
| 2026-02-01 | James Kastenmayer | General Counsel | Other Derivative Acquisition | +130,000 | $22.67 |
| 2025-12-09 | Hillhouse Capital Management, Ltd. | -- | Open Market Disposition | -555,555 | $23.37 |
| 2025-07-10 | Robin LaChapelle | Co-Founder & COO | Derivative Exercise and Retained | +11,153 | $2.28 |
| 2025-06-17 | Kristine Peterson | Director | Other Derivative Acquisition | +15,502 | $24.89 |
| 2025-06-17 | Merdad Parsey | Independent Director | Other Derivative Acquisition | +15,502 | $24.89 |
| 2025-06-17 | John Hohneker | Director | Other Derivative Acquisition | +15,502 | $24.89 |
| 2025-06-17 | Christian Nolet | Independent Director | Other Derivative Acquisition | +15,502 | $24.89 |
| 2025-04-27 | Merdad Parsey | Independent Director | Other Derivative Acquisition | +28,346 | $20.92 |
| 2025-02-02 | Zhengbin Yao | Chairperson & CEO | Other Derivative Acquisition | +380,000 | $27.56 |
| 2025-02-02 | Robin LaChapelle | Co-Founder & COO | Other Derivative Acquisition | +120,000 | $27.56 |
| 2025-02-02 | Stuart Lutzker | Co-Founder, President of Research & Development and Director | Other Derivative Acquisition | +120,000 | $27.56 |
| 2025-02-02 | Winston Kung | Chief Financial Officer | Other Derivative Acquisition | +120,000 | $27.56 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:17:48 · For reference only, not investment advice and not tailored to your situation.